Greenhill logo
Top Image
Home > Our Business > By Industry > Healthcare

Greenhill has considerable transaction experience and a global network of corporate relationships in the Healthcare sector.  Our managing directors and professionals in North America, the United Kingdom, Continental Europe, Australia and Japan have executed many of the most significant and complex transactions for some of the leading companies in the industry.

Our experience in the Healthcare industry encompasses the following sub-sectors; pharmaceuticals, biotechnology, medical devices, medical services and other specialized sub-sectors. 

Below we highlight a few of the transactions on which we have advised in this area:

NA MannKind Corporation
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits
$1.3 billion Siemens Health Services
Advising Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
Cerner Corporation
$90 million Clinuvel Pharmaceuticals Limited
Advising Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
Retrophin, Inc.
$28 billion Forest Laboratories Inc.
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
Actavis plc
NA Unfors Raysafe AB
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
Fluke Biomedical Corporation
NA Fidelis SeniorCare Inc. (Michigan Heath Plan)
Advising Fidelis SeniorCare Inc., a healthcare provider focused on the care of the elderly, on the sale of a majority of its SecureCare Michigan health plan to Centene Corporation, a managed care provider focused on the Medicaid space
Centene Corporation
$8.5 billion Warner Chilcott, plc
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
Actavis, Inc.
$7.3 billion Coventry Health Care Inc.
Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna
$4.0 billion Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
$513 million ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
Bausch + Lomb, Inc.
$689 million iNova Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
Valeant Pharmaceuticals
$398 million American Dental Partners, Inc.
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
JLL Partners
$609 million Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
Royalty Pharma
NA Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
$12.9 billion Alcon, Inc.
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
Novartis AG
$256 million Maxinutrition Group Holdings Limited
Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity
GlaxoSmithKline Plc
$500 million Medicity, Inc.
Advised Aetna Inc. on its acquisition of Medicity, Inc., a leading provider of technology solutions to enable the secure access and exchange of healthcare information
Aetna Inc.
$118 million Healthcare Australia
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
Healthcare Locums
$234 million Taro Pharmaceutical Industries
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
Sun Pharmaceutical Industries Ltd.
NA Breast Care Business of Ethicon-Endo Surgery
Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery
Devicor Medical Products, Inc. (a GTCR portfolio company)
$225 million Medegen, Inc
Advised Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company
CareFusion Corporation
NA Heartscape Technologies, Inc.
Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company
Roper Industries, Inc.
$327 million Enzon Pharmaceuticals, Inc.
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
Sigma-Tau Pharmaceuticals
$155 million Monogram Biosciences, Inc.
Advised LabCorp on the acquisition of Monogram Biosciences, a molecular diagnostics company focused on guiding and improving the treatment of serious infectious diseases and cancer
Laboratory Corporation of America Holdings
$46.9 billion Genentech, Inc.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
Roche Holding Ltd.
$53 million Biotage (Biosystems division)
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research
Qiagen NV
$6.7 billion Applied Biosystems Group
Provided fairness opinion to the Board of Directors of the Applera Corporation on the merger of its Applied Biosystems business, which serves the life science industry, with the Invitrogen Corporation, creating a global leader in biotechnology reagents and systems
Invitrogen Corporation
$3.4 billion Ventana Medical Systems, Inc.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a U.S. based provider of histopathology diagnostic equipment
Roche Holding Ltd.
$3.3 billion Cardinal Health, Inc., Pharmaceutical Technologies and Services division
Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries
The Blackstone Group
$4.2 billion Kos Pharmaceuticals, Inc.
Advised Kos Pharmaceuticals, Inc., a specialty pharmaceutical provider of cardiovascular and respiratory drugs, on its sale to Abbott Laboratories
Abbott Laboratories
$21.2 billion Schering AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
Bayer AG
Print E-mail
Case Study
Lion Pty Ltd.
Lion Pty Ltd.
Greenhill advised Lion Pty Ltd, a subsidiary of Kirin Holdings and one of Australia and New Zealand’s leading beverage, food and dairy companies, on the acquisition of the 63.
read more »

more case studies »

© 2014 Greenhill & Co., Inc. All rights reserved.